Investigational New Drugs

, Volume 11, Issue 2–3, pp 187–195 | Cite as

Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD)

  • Susanne Danhauser-Riedl
  • Edith Hausmann
  • Hans-D. Schick
  • Rita Bender
  • Hermann Dietzfelbinger
  • Johann Rastetter
  • Axel-R. Hanauske
Phase I Studies


Coupling of anthracyclines to high-molecular-weight carriers may alter drug disposition and improve antitumor effects. We have performed a clinical phase I trial of doxorubicin coupled to dextran (70000 m.w.). The drug was administered as single dose i.v. every 21–28 days. Thirteen patients have received a total of 24 courses (median 2; range 1–3). At the starting dose of 40 mg/m2 doxorubicin equivalent (DOXeq), WHO grade IV thrombocytopenia was noted in 2/2 patients. WHO grade IV hepatotoxicity and WHO grade III cardiotoxicity were noted in a patient with preexisting heart disease. Five patients were treated with 12.5 mg/m2 DOXeq. Maximal toxicity at this dose level was WHO grade III thrombocytopenia and local phlebitis (WHO grade II) in 1/5 patients, elevation of alkaline phosphatase (WHO grade III) and WHO grade III vomiting in another patient. Subsequently, five patients received 20 mg/m2 DOXeq. Hepatotoxicity was noted in 5/5 patients (1 × WHO grade IV, 1 × WHO grade III). Thrombocytopenia was noted in 3/5 patients (1 × WHO grade IV, 2 × WHO grade III). At 12.5 mg/m2 DOXeq, a patient diagnosed with a malignant fibrous histiocytoma had stable disease for 4 months. Pharmacokinetic analyses of total and free doxorubicin were performed in plasma and urine. The maximum peak plasma concentration (ppc) for total DOX was 12.3 μg/ml at 40 mg/m2 DOXeq. The area under the plasma concentration time curve (AUC) ranged from 28.83–80.21 μg/ml*h with dose-dependent elimination half lives (t1/2α: 0.02–0.87 h;1/2β: 2.69–11.58 h;1/2γ: 41.44–136.58 h). We conclude that the maximal tolerated dose (MTD) of AD-70 using this schedule is 40 mg/m2 DOXeq. The recommended dose for clinical phase II studies is 12.5 mg/m2 DOXeq.

Key words

phase I dextran-conjugated doxorubicin pharmacokinetics 



Alanine Aminotransferase


Aspartate Aminotransferase




Doxorubicin Equivalent




High Pressure Liquid Chromatography


Lethal Dose for 10% of individuals


Maximal Tolerated Dose


Peak Plasma Concentration


World Health Organisation


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Myers CE, Chabner BA: Anthracyclines. In: B.A. Chabner and J.M. Collins (eds.), Cancer Chemotherapy: Principles and Practice, pp. 356–381. J.B. Lippincott Company, Philadelphia, 1990Google Scholar
  2. 2.
    Henderson IC, Frei III E: Adriamycin and the heart. New Engl J Med 300:310–312, 1979Google Scholar
  3. 3.
    Duncan R: Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs 3:175–210, 1992Google Scholar
  4. 4.
    Bernstein A, Hurwitz E, Marnon R, Arnon R, Sela M, Wilchek M: Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J Natl Cancer Inst 60:379–384, 1978Google Scholar
  5. 5.
    Levi-Schaffer F, Bernstein A, Meshorer A, Arnon R: Reduced toxicity of daunorubicin by conjugation to dextran. Cancer Treat Rep 66:107–112, 1982Google Scholar
  6. 6.
    Ueda Y, Kikukawa A, Munechika K, Yamanouchi K, Yokoyama K: Comparative distribution of adriamycin linked to oxidized dextran and free adriamycin in tumorbearing animals. Proc Intern Symp Control Rel Bioact Mater 16:142–143, 1989Google Scholar
  7. 7.
    Ueda Y, Munechika K, Kikukawa A, Kanoh Y, Yamanouchi K, Yokoyama K: Comparison of efficacy, toxicity and pharmacokinetics of free adriamycin and adriamycin linked to oxidized dextran in rats. Chem Pharm Bull 37:1639–1641, 1989Google Scholar
  8. 8.
    Kikukawa A, Munechika K, Ueda Y, Yamanouchi K, Yokoyama K, Tsukagoshi S: Tissue concentration of adriamycin and adriamycin-oxidized dextran conjugate in tumor bearing rats and mice. Drug Delivery Syst 5:255–260, 1990Google Scholar
  9. 9.
    Yamaoka K, Tanigawara Y, Kakagawa T, Uno T: A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharm Dyn 4:879–885, 1981Google Scholar
  10. 10.
    Yamaoka K, Nakagawa T: A nonlinear least squares program based on differential equations, MULTI (RUNGE), for microcomputers. J Pharm Dyn 6:595–606, 1983Google Scholar
  11. 11.
    Sogame Y, Munechika K, Kawabata Y, Ueda Y, Tsuda Y, Yokoyama K, Tsukagoshi S: Distribution of adriamycinoxidized dextran conjugate (ADM-OXD) in tumor-bearing rats. Drug Delivery Syst 7:181–185, 1992Google Scholar
  12. 12.
    Yokoyama K, Ueda Y, Kikukawa A, Yamanouchi K: Drug Delivery Systems: The Industrial View. In: G. Gregoriadis (ed.), Targeting of Drugs, pp. 137–153. Plenum Press, New York, 1990Google Scholar
  13. 13.
    Munechika K, Nakae T, Kikukawa A, Ueda Y, Yamanouchi K, Yokoyama K, Tsukagoshi S: Intracellular behavior of adriamycin-oxidized dextran conjugate. Drug Delivery Syst 6:127–131, 1991Google Scholar
  14. 14.
    Iwai K, Meada H, Konno T: Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and x-ray image. Cancer Res 44:2115–2121, 1984Google Scholar
  15. 15.
    Fujita H, Okamoto M, Takao A: Pharmacokinetics of adriamycin-oxidized dextran conjugate (ADM-OXD) in experimental animals. Drug Delivery Syst 6:133–138, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Susanne Danhauser-Riedl
    • 1
  • Edith Hausmann
    • 2
  • Hans-D. Schick
    • 1
  • Rita Bender
    • 3
  • Hermann Dietzfelbinger
    • 1
  • Johann Rastetter
    • 1
  • Axel-R. Hanauske
    • 1
  1. 1.Department of Medicine I, Division of Hematology/OncologyTechnische Universität MünchenMunich 80
  2. 2.Medizinische HochschuleInstitute of ToxicologyHannover
  3. 3.Alpha Therapeutic GmbHLangenGermany

Personalised recommendations